These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15262262)

  • 1. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
    Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
    Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
    Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
    Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
    Kasperzyk JL; El-Abbadi MM; Hauser EC; D'Azzo A; Platt FM; Seyfried TN
    J Neurochem; 2004 May; 89(3):645-53. PubMed ID: 15086521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
    Denny CA; Heinecke KA; Kim YP; Baek RC; Loh KS; Butters TD; Bronson RT; Platt FM; Seyfried TN
    J Neurochem; 2010 Jun; 113(6):1525-35. PubMed ID: 20374428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
    Andersson U; Butters TD; Dwek RA; Platt FM
    Biochem Pharmacol; 2000 Apr; 59(7):821-9. PubMed ID: 10718340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
    Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
    Ranes MK; El-Abbadi M; Manfredi MG; Mukherjee P; Platt FM; Seyfried TN
    Br J Cancer; 2001 Apr; 84(8):1107-14. PubMed ID: 11308262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
    Jeyakumar M; Smith DA; Williams IM; Borja MC; Neville DC; Butters TD; Dwek RA; Platt FM
    Ann Neurol; 2004 Nov; 56(5):642-9. PubMed ID: 15505823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
    Priestman DA; van der Spoel AC; Butters TD; Dwek RA; Platt FM
    Diabetes Obes Metab; 2008 Feb; 10(2):159-66. PubMed ID: 18190430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate reduction therapy for glycosphingolipid storage disorders.
    Lachmann RH; Platt FM
    Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities.
    Suganuma R; Walden CM; Butters TD; Platt FM; Dwek RA; Yanagimachi R; van der Spoel AC
    Biol Reprod; 2005 Apr; 72(4):805-13. PubMed ID: 15576825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.
    Arthur JR; Lee JP; Snyder EY; Seyfried TN
    Neurochem Res; 2012 Jun; 37(6):1335-43. PubMed ID: 22367451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
    Jeyakumar M; Norflus F; Tifft CJ; Cortina-Borja M; Butters TD; Proia RL; Perry VH; Dwek RA; Platt FM
    Blood; 2001 Jan; 97(1):327-9. PubMed ID: 11133779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
    Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M
    Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
    Elliot-Smith E; Speak AO; Lloyd-Evans E; Smith DA; van der Spoel AC; Jeyakumar M; Butters TD; Dwek RA; d'Azzo A; Platt FM
    Mol Genet Metab; 2008 Jun; 94(2):204-11. PubMed ID: 18387328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice.
    Wu YP; Proia RL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8425-30. PubMed ID: 15155903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
    Butters TD; Dwek RA; Platt FM
    Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
    Pelled D; Lloyd-Evans E; Riebeling C; Jeyakumar M; Platt FM; Futerman AH
    J Biol Chem; 2003 Aug; 278(32):29496-501. PubMed ID: 12756243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing.
    Platt FM; Neises GR; Karlsson GB; Dwek RA; Butters TD
    J Biol Chem; 1994 Oct; 269(43):27108-14. PubMed ID: 7929454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
    Andersson U; Reinkensmeier G; Butters TD; Dwek RA; Platt FM
    Biochem Pharmacol; 2004 Feb; 67(4):697-705. PubMed ID: 14757169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.